Debate Continues Over Ebola Vaccination Strategy In DRC, As WHO Announces Use Of 2nd Experimental Vaccine

Associated Press: 2nd Ebola vaccine to be used in Congo, as U.N. efforts slammed
“The World Health Organization on Monday announced Congo will start using a second experimental Ebola vaccine, as efforts to stop the deadly outbreak are stalled and Doctors Without Borders criticizes vaccination efforts to date…” (Cheng, 9/23).

NPR: Doctors Without Borders Calls For More Transparency In Distribution Of Ebola Vaccine
“…Dr. Isabelle Defourny, the group’s director of operations, said in a statement Monday that at least 2,000 people could be receiving the vaccine each day, instead of the maximum of 1,000 who are vaccinated daily at present. She called for WHO to supply more vaccines to medical teams…” (Zialcita, 9/23).

STAT: Vaccination strategy in long-running Ebola outbreak comes under fire
“…Strident debate about how to use vaccine in this outbreak has raged for months with disagreements swirling about both the strategy behind use of the Merck vaccine — the only Ebola vaccine for which there are Phase III efficacy data — and about how and where to deploy the J&J product, for which there aren’t yet human efficacy data…” (Branswell, 9/23).

Additional coverage of vaccine use in the DRC Ebola outbreak is available from Al Jazeera, The Hill, and New York Times.

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.